OHSU Team Develops Assay to Help Pick Tyrosine Kinase Inhibitors Against AML

The assay, developed with technology licensed from MolecularMD, “rapidly delivers the information [and] has the capability of telling researchers which actual proteins from the tyrosine kinase family are contributing to an individual patient's cancer.”

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.